Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Kings College London Ink Deal on miRNA Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma Life Science today announced a licensing deal with King's College London for the development and commercialization of technology to identify and validate miRNA targets in research and clinical diagnostics.

The technology was developed at the division of cancer studies at King's College. No further details about the technology or terms of the deal were disclosed.

miRNAs are critical regulators of gene expression in eukaryotic cells, and aberrant expression in miRNAs has been implicated in numerous disease states, making them important targets in clinical research in oncology, wound healing, and infectious disease, according to Sigma Life Science, the biological products and services research business of Sigma-Aldrich. However, the specific targets of most miRNAs are unknown, and current methods of identifying miRNA targets are "laborious and inefficient" relying on computer algorithms and validation by in vitro assays, the company added.

In a statement, Joop Gaken, lead researcher on the project at King's College, said that the method developed by him and his colleagues "is expected to enable the straightforward identification of target genes that are strongly regulated by a given miRNA, helping to elucidate important gene regulation events in vivo."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.